Back to Speakers

Adam Lepley, PhD, ATC

Adam Lepley, PhD, ATC

Dr. Adam Lepley is a clinical associate professor of Applied Exercise Science, Athletic Training, and Movement Science at the University of Michigan School of Kinesiology. Additionally, Dr. Lepley serves as the clinical education coordinator for the Athletic Training program and director of the Michigan Performance Research Laboratory (MiPR) within the Exercise & Sport Science Initiative. He earned a bachelor’s degree in Athletic Training from Grand Valley State University, master’s degree in Kinesiology from the University of Minnesota, and PhD in Exercise Science from the University of Toledo.

Dr. Lepley's research agenda is focused on understanding neural contributions to muscle dysfunction and their involvement in lower extremity biomechanical and self-reported disability following traumatic knee joint injuries. He applies foundational skills in neurophysiology to musculoskeletal injuries in order to investigate systemic effects that joint injury has on clinical function and athletic performance. The overall goal of this research is to identify the origins of persistent neuromuscular dysfunction for the purpose of maintaining long-term health outcomes following acute injury.

Content Where I Am Featured

Sort By
Search by Favorites
Search by Keyword
  • Contains 5 Component(s), Includes Credits

    Clinical outcomes following anterior cruciate ligament reconstruction (ACLR) remain unsatisfactory, with elevated rates of re-injury and osteoarthritis reported within 1-2 decades. Quadriceps dysfunction is thought to influence such outcomes by promoting deleterious biomechanical adaptations, yet traditional rehabilitation often fails to restore muscle function beyond return-to-activity. Advances in our understanding of underlying contributions to persistent muscle weakness have shaped the development of novel rehabilitation approaches. To address the burden of ACLR, we will (1) highlight evidence of the underlying mechanisms and clinical impact of quadriceps dysfunction, and (2) provide clinicians with novel therapeutic interventions to optimize clinical outcomes over the lifespan.